More recently, reductions in breast density with tamoxifen and aromatase inhibitors (AI) as a marker of treatment response was investigated in women with breast cancer, by comparing to a control group of untreated women without breast cancer; the first study of its kind to validate automated measures of breast density [182]. Here, CYP19A1 is linked to breast carcinoma.